Stevanato Group S.p.a. · NYSE:STVN
Stevanato — Q3 2021 Earnings Presentation
20 slides from Stevanato's earnings presentation, Nov 9, 2021
Slide 1: Third Quarter 2021 Financial Results
Third Quarter 2021 Financial Results November 9, 2021 Exhibit 99.1
Slide 2: Safe-Harbor Statement
Safe-Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements which include, or may include, words such as "raising", "believe", "potential", "increased", "future", "remain", "growing", "expect", "foreseeable", "expected", "to be", "includes", "estima
Slide 3: Third Quarter 2021 Earnings Call Speakers
Franco Stevanato Executive Board Chairman Stevanato Group Third Quarter 2021 Earnings Call Speakers Franco Moro CEO Marco Dal Lago CFO Lisa Miles SVP IR Third Quarter 2021 Financial Results
Slide 4: Creating and Driving Long-Term Shareholder Value
.ADVANCING PROGRESS ON: Growing industrial footprint to meet customer demand Investing in R&D to accelerate market position and increase pipeline for proprietary solutions (Alba, Nexa and DDS) Expanding in U.S. and China Building multi-year pipeline of opportunities, weighted towards biologics EMPLO
Slide 5: Q3 2021 Key Performance Indicators
Q3 2021 KEY PERFORMANCE INDICATORS €214.5M Q3 21 Revenue 37% YoY Revenue Growth €51.4M Q3 21 Adj. EBITDA* 24% Q3 21 Adj. EBITDA Margin* €0.10 Q3 21 Adjusted Diluted EPS* €310M Q3 21 Order Intake €834M Backlog 23% Q3 21 Revenue from HVS Q3 2021 Operating and Financial Results Highlights Strong sales,
Slide 6: Investments in Capacity Expansions Remain On Track
Investments in Capacity Expansions Remain On Track BOOSTING PRESENCE IN FAST GROWING U.S. MARKET Broke ground in October; recruiting, hiring, training for key managerial positions Will expand production of EZ-Fill® vials and syringes; meet performance demands of biologics EZ-Fill® hub strengthen pre
Slide 7: Current Global Trends
Current Global Trends Supply Chain Trends To date, no significant disruption in supply chains Taken precautionary steps; increased materials on hand and keeping more inventory available In short term, temporary pressure from logistical expenses Rising input costs are near-term challenge; managing ca
Slide 8: Solid Fundamentals and Robust Demand Helped Deliver DD Growth
Solid Fundamentals and Robust Demand Helped Deliver DD Growth REVENUE (IN € MILLIONS) 2 Revenue growth calculated on a constant currency basis was 36%. Constant currency is a non-GAAP measure. Please refer to slides 13-19 for a reconciliation of non-GAAP measures 3 Approximately 16% of revenue from
Slide 9: Q3 2021 Strong Results Across Our Business
ADJUSTED EBITDA* 24.0% 24.6% 33% Q3 2021 Strong Results Across Our Business overall_0_132573506445777536 columns_7_132584762853721572 3_1_132573506445777536 6_1_132573506445777536 9_1_132573506445777536 12_1_132573506445777536 13_1_132573506445777536 14_1_132573506445777536 15_1_132573506445777536 1
Slide 10: Financial Overview Continued: Q3 2021 Segment Overview
Financial Overview Continued: Q3 2021 Segment Overview BIOPHARMACEUTICAL AND DIAGNOSTIC SEGMENT (BDS) 31% YoY revenue growth to €172.8 million (third party sales) 29% increase in HVS; 32% increase in other containment compared to same period last year Gross profit margin of 31.2% was lower due to pr
Slide 11: Liquidity, Capital Allocation, M&A
Liquidity, Capital Allocation, M&A STRONG LIQUIDITY Net proceeds of €380M from IPO (includes overallotment) Mix of cash from operations, debt facility capacity and proceeds are ample to address future liquidity needs CAPITAL ALLOCATION PRIORITIES HVS capacity expansion to satisfy market demands Rese
Slide 12: 2021 Guidance
2021 Guidance Increasing Revenue and Raising the Bottom End of Adjusted Diluted EPS and Adjusted EBITDA Updating Full Year 2021 Guidance €825M - €835M Revenue €0.45 - €0.47 Adj. Diluted EPS* €214M - €217M Adj. EBITDA* ~252.7M Weighted Average Shares Outstanding 5 *Adjusted EBITDA and adjusted dilute
Slide 13: Notes to Non-GAAP Financial Measures
Notes to Non-GAAP Financial Measures: This presentation contains non-GAAP measures. Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency Revenue, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Oper
Slide 14: Reconciliation of Constant Currency Revenue
Reconciliation of Non-GAAP Measures (Unaudited) Reconciliation of Constant Currency Reconciliation of Revenue to Constant Currency Revenue (Amounts in € millions) Third Quarter 2021 Financial Results
Slide 15: Reconciliation of EBITDA
Reconciliation of Non-GAAP Measures (Unaudited) Reconciliation EBITDA Reconciliation of EBITDA (Unaudited) (Amounts in € millions) Third Quarter 2021 Financial Results
Slide 16: Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Net Profit and Diluted EPS
Reconciliation of Non-GAAP Measures (Unaudited) Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Net Income Taxes, Net Profit and Diluted EPS (Unaudited) (Amounts in € millions, except per share data) 1 During the three and the nine months ended September 30, 2021, the Group recorde
Slide 17: Footnotes to Non-GAAP Reconciliations
9 During the three and the nine months ended September 30, 2021, the Group recorded €0.2 million and €1.2 million respectively in restructuring and related charges for the consolidation of Balda plants in the U.S. These costs impacted only Biopharmaceutical and Diagnostic Solutions Segment. 10 Durin
Slide 18: Reconciliation of Free Cash Flow
Reconciliation of Non-GAAP Measures (Unaudited) Reconciliation of Free Cash Flow Free Cash Flow (Unaudited) (Amounts in € millions) Third Quarter 2021 Financial Results
Slide 19: Reconciliation of Adjusted Guidance
Reconciliation of Non-GAAP Measures (Unaudited) Reconciliation of Adjusted Guidance Reconciliation of 2021 Guidance for Adjusted EBITDA, Adjusted Operating Profit, Adjusted Net Profit and Adjusted Diluted EPS (Unaudited) (Amounts in € millions, except per share data) Third Quarter 2021 Financial Res
Slide 20: Contacts
Contacts: Media Stevanato Group media@stevanatogroup.com Investor Relations Lisa Miles Lisa.miles@stevanatogroup.com